CD22 and B-cell acute lymphoblastic leukemia: Inotuzumab ozogamicin, a humanized CD-22–targeting ADCs, is utilized as a monotherapy in the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (21).